Skip to main content

Advertisement

SpringerLink
Log in

CANCER THERAPY

Neoadjuvant immune-checkpoint blockade in resectable colon cancer

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Neoadjuvant checkpoint blockade achieves deep or complete pathologic responses in patients with mismatch-repair-deficient and mismatch-repair-proficient early colon cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Neoadjuvant CTLA-4–PD-1 blockade in colon cancer.

References

  1. Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  Google Scholar 

  2. Chalabi, M. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0805-8 (2020).

  3. Wei, S. C., Duffy, C. R. & Allison, J. P. Cancer Discov. 8, 1069–1086 (2018).

    Article  Google Scholar 

  4. Tumeh, P. C. et al. Nature 515, 568–571 (2014).

    Article  CAS  Google Scholar 

  5. Thommen, D. S. et al. Nat. Med. 24, 994–1004 (2018).

    Article  CAS  Google Scholar 

  6. Fairfax, B. P. et al. Nat. Med. 26, 193–199 (2020).

    Article  CAS  Google Scholar 

  7. Yost, K. E. et al. Nat. Med. 25, 1251–1259 (2019).

    Article  CAS  Google Scholar 

  8. Siddiqui, I. et al. Immunity 50, 195–211.e10 (2019).

    Article  CAS  Google Scholar 

  9. Łuksza, M. et al. Nature 551, 517–520 (2017).

    Article  Google Scholar 

  10. Liu, J. et al. Cancer Discov. 6, 1382–1399 (2016).

    Article  CAS  Google Scholar 

  11. Pai, C. S. et al. Immunity 50, 477–492.e8 (2019).

    Article  CAS  Google Scholar 

  12. Angelova, M. et al. Cell 175, 751–765.e16 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, and Department of Oncology, University of Lausanne and University Hospital of Lausanne, Lausanne, Switzerland

    George Coukos

Authors
  1. George Coukos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Coukos.

Ethics declarations

Competing interests

G.C. has received grants or research support from or is co-investigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance and Kite, and has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coukos, G. Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nat Med 26, 473–474 (2020). https://doi.org/10.1038/s41591-020-0826-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-020-0826-3

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation